Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC # 683864) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma
Conditions
Interventions
Laboratory Biomarker Analysis
Megestrol Acetate
+2 more
Locations
108
United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, United States
Stanford Cancer Institute
Palo Alto, California, United States
University of California San Diego
San Diego, California, United States
Colorado Gynecologic Oncology Group
Aurora, Colorado, United States
University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado, United States
Hartford Hospital
Hartford, Connecticut, United States
Start Date
September 1, 2008
Primary Completion Date
February 1, 2017
Completion Date
February 1, 2017
Last Updated
July 23, 2019
NCT05919264
NCT05969860
NCT06253494
NCT04704661
NCT05039801
NCT06349642
Lead Sponsor
National Cancer Institute (NCI)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions